SU‐FF‐T‐90: Adaptive Radiotherapy Treatment Re‐Planning For Head And Neck Cancer Patients
Purpose: To demonstrate the need for adaptive treatment re‐planning in Head and Neck (HN 1% of the new PTV received <46Gy (prescribed dose: 58Gy). The maximum spinal cord dose increased 27.1% from 27.7Gy to 35.2Gy. The mean left parotid dose was the same. The mean right parotid dose increased by 15.8%. Conclusions: For H&N cancer, adaptive mid‐treatment re‐planning should be considered for more accurate dose delivery especially when significant clinical response is noted on physical exam or daily/weekly imaging. Significant changes in the DVH can take place for normal structure as well as the CTV and the CT‐GTV due to anatomical changes during the course of treatment.